Organovo Holdings Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	2.6yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO

Organovo Holdings has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Keith Murphy	Executive Chairman	4.2yrs	US$789.99k	0.58% $ 37.3k
Thomas Hess	President & CFO	2.9yrs	US$199.32k	no data
Vaidehi Joshi	Director of Discovery Biology & Director	2.4yrs	US$119.05k	0.13% $ 8.2k
Curtis Tyree	Senior Vice President of Strategy & Business Development	2.6yrs	no data	no data

2.6yrs

Average Tenure

52yo

Average Age

Experienced Management: 4OR1's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Keith Murphy	Executive Chairman	4.2yrs	US$789.99k	0.58% $ 37.3k
Vaidehi Joshi	Director of Discovery Biology & Director	2.5yrs	US$119.05k	0.13% $ 8.2k
Adam Stern	Independent Director	4.2yrs	US$124.15k	0.13% $ 8.2k
Alison Milhous	Independent Director	4yrs	US$132.25k	0.13% $ 8.2k
Douglas Cohen	Lead Independent Director	4yrs	US$132.25k	0.21% $ 13.2k
David Gobel	Independent Director	4yrs	US$132.25k	0% $ 0

4.0yrs

Average Tenure

52.5yo

Average Age

Experienced Board: 4OR1's board of directors are considered experienced (4 years average tenure).

Organovo Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

High number of new and inexperienced directors

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

High number of new and inexperienced directors

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Recent updates

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

New major risk - Financial position

First quarter 2025 earnings released: US$0.23 loss per share (vs US$0.46 loss in 1Q 2024)

Organovo Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2024 earnings released: US$1.60 loss per share (vs US$1.98 loss in FY 2023)

Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Third quarter 2024 earnings released: US$0.40 loss per share (vs US$0.38 loss in 3Q 2023)

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.605728 million.

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

New minor risk - Shareholder dilution

New major risk - Market cap size

Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results

New major risk - Market cap size

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Holdings, Inc. announced delayed annual 10-K filing

High number of new and inexperienced directors

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease

High number of new and inexperienced directors

BICO Reaches Beneficial and Sustainable Solution with Organovo

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Organovo Holdings, Inc. Guides on Patent Portfolio and Successful IPR Defense of Two Patents

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

High number of new and inexperienced directors

Organovo Holdings, Inc. Enter into Two Lease Agreements Between Company and San Diego Inspire 1, LLC

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Growth Index

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Index

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age